

FIG. 1 Post Ig disruption gel filtration chromatogram.





FIG. 2.


Silver stained gel, c-myc purification, post immunoaffinity.



- 1 - major c-myc peak, room temp purification
- 2 - major c-myc peak, 4°C purification
- 3 - minor c-myc peak, room temp purification
- 4 - minor c-myc peak, 4°C purification

FIG. 3.

Immunoproped blot, c-myc purification, post immunoaffinity.



1 - major c-myc peak, room temp purification  
2 - major c-myc peak, 4°C purification  
3 - minor c-myc peak, room temp purification  
4 - minor c-myc peak, 4°C purification  
5 - molecular weight markers

FIG. 4.

Serum Samples vs MUC1 from Various Body Fluids.




Fig. 5.

Normal Serum Samples vs MUC1 from Various Body Fluids.




FIG. 6.

## Serum samples vs normal and tumour associated CA125





FIG. 7.

Concentration of MUC1 in sera and fluids derived from individuals with cancer.




PE - pleural effusion.

AF - ascitic fluid.

*FIG. 8.*


Concentration of MUC1 in serum and fluids derived from an individual with cancer.



WDF – wound draining fluid

FIG. 9.

Reactivity of human anti-MUC1 antibodies purified against cancer associated MUC1 from seroma.



Pt-nMUC1 – urinary MUC1 from patient M, 2 years prior to cancer diagnosis.  
 Pt-MUC1 – MUC1 derived from the seroma of patient M, after diagnosis with cancer.  
 BSA-AG – bovine serum albumen conjugated to MUC1 protein core peptide.

FIG. 10.

Serum reactivity against MUC1 purified from Ascitic Fluid.




FIG. 11.

Serum reactivity against MUC1 purified from Pleural Effusions.




FIG. 12.  
Titration of PE MUC1

